Research programme: CAR-NK cell therapies - Senti Biosciences
Latest Information Update: 28 May 2025
At a glance
- Originator Senti Biosciences
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
- No development reported Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 14 Apr 2023 Preclinical trials in Acute myeloid leukaemia in USA (IV) prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)